A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Inclusion Criteria:

1. Subject is ≥ 18 years and ≤ 75 years of age at the time of signing the informed
consent form (ICF).

2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

3. Histologically proven diffuse large B-cell lymphoma (DLBCL) NOS (de novo or
transformed indolent NHL), high grade B-cell lymphoma with MYC and BCL2 and/or BCL6
rearrangements with DLBCL histology (double/triple-hit lymphoma [DHL/THL]), primary
mediastinal (thymic) large B-cell lymphoma (PMBCL), T cell/histiocyte-rich large
B-cell lymphoma (THRBCL) or follicular lymphoma grade 3B. Enough tumor material must
be available for confirmation by central pathology.

4. Refractory or relapsed within 12 months from CD20 antibody and anthracycline
containing first line therapy.

5. [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) positive lesion at
screening.

6. Adequate organ function

7. Participants must agree to use effective contraception

Exclusion Criteria:

1. Subjects not eligible for hematopoietic stem cell transplantation (HSCT).

2. Subjects planned to undergo allogeneic stem cell transplantation.

3. Subjects with, primary cutaneous large B-cell lymphoma, EBV (Epstein-Barr virus)
positive DLBCL of the elderly and Burkitt lymphoma.

4. Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the
subject has been free of the disease for ≥ 2 years with the exception of the following
noninvasive malignancies:

- Basal cell carcinoma of the skin

- Squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix

- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer (T1a or T1b using the TNM
[tumor, nodes, metastasis] clinical staging system) or prostate cancer that is
curative.

- Other completely resected stage 1 solid tumor with low risk for recurrence

5. Treatment with any prior gene therapy product.

6. Subjects who have received previous CD19-targeted therapy.

7. History of or active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
infection.

8. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection
(including tuberculosis) despite appropriate antibiotics or other treatment.

9. Active autoimmune disease requiring immunosuppressive therapy.

10. History of any one of the following cardiovascular conditions within the past 6 months
prior to signing the ICF: Class III or IV heart failure as defined by the New York
Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction,
unstable angina, or other clinically significant cardiac disease.

11. History or presence of clinically relevant central nervous system (CNS) pathology

12. Pregnant or nursing (lactating) women.